SavedAdd your journal

Journals / Anatomy / 2022 / Cilt: 16 Sayı: 2

In vivo experimental models of schizophrenia: mechanisms, features, advantages, disadvantages

Zeynep Mine ALTUNAY
Aysel ALPHAN
Esat ADIGÜZEL
Journal
Anatomy
Pages
114–123
Publication Date
2022-08-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

And also we briefly indicate the molecular mechanisms of the experimental models that mimic schizophrenia-like symptoms and its behavioral outputs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The experimental models of human diseases are indispensable research methods which are undesirable to be tested on humans.
📊
Key Findings & Data:It is inevitable for researchers who continue their careers in the field of anatomy to be aware of these methods.
💡
Conclusion & Impact:And also we briefly indicate the molecular mechanisms of the experimental models that mimic schizophrenia-like symptoms and its behavioral outputs.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:animal models · experimental models · mental disorders

Abstract

The experimental models of human diseases are indispensable research methods which are undesirable to be tested on humans. It is inevitable for researchers who continue their careers in the field of anatomy to be aware of these methods. Here, experimental schizophrenia models that can be used to reveal brain functions and also pathophysiology of schizophrenia are discussed. It is aimed to give general information about the features of the experimental schizophrenia models that can be used by researchers in morphological sciences; therein the references should be considered for the setup of the experimental schizophrenia models. In this review, in vivo model of schizophrenia used on etiopathogenesis, pathophysiology, drug discovery and behavioral analysis are represented. And also we briefly indicate the molecular mechanisms of the experimental models that mimic schizophrenia-like symptoms and its behavioral outputs.

🔖

Cite This Article

ALTUNAY, Z. M., ALPHAN, A., ADIGÜZEL, E. (2022). In vivo experimental models of schizophrenia: mechanisms, features, advantages, disadvantages. Anatomy, Cilt: 16 Sayı: 2, 114–123. https://ajindex.com/articles/936255

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. Lancet 1995;346:477–81
  2. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan ME, Nakazawa K. Postnatal NMDA reseptor ablation in corticolimbik interneurons confers schizophrenia like phenotypes. Nat Neurosci 2010;13:76–83
  3. Andreassen OA, Thompson WK, Dale AM. Boosting the power of schizophrenia genetics by leveraging new statistical tools. Schizophr Bull 2014;40:13–17
  4. Uzun Ö. Pozitif – negatif belirtiler. In: Ceylan E, Çetin M, editors. Şizofreni. Vol
  5. İstanbul: Yerküre Tanıtım ve Yayıncılık; 2005. p. 643–56
  6. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam’s razor. Schizophr Bull 2010;36:359–69
  7. Bayer TA, Falkai P, Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the “two hit hypothesis”. J Psychiatr Res 1999;33:543–8
  8. Kim DH, Stahl SM. Antipsychotic drug development. Curr Top Behav Neurosci 2010;4:123–39
  9. Taly A. Novel approaches to drug design for the treatment of schizophrenia. Exp Opin Drug Discov 2013;8:1285–96
  10. Murray RM, Lappin J, Di Forti M. Schizophrenia: from developmental deviance to dopamine dysregulation. Eur Neuropsycho-pharmacol 2008;18:S129–34
  11. Inta D, Monyer H, Sprengel R, Meyer-Lindenberg A, Gass P. A comprehensive review: mice with genetically altered glutamate receptors as models of schizophrenia. Neurosci Biobehav Rev 2010; 34:285–94
  12. Yamazaki M, Harada K, Yamamoto N, Yarimizu J, Okabe M, Shimada T, Ni K, Matsuoka N. ASP5736, a novel 5-HT5A receptor antagonist, a meliorates positive symptoms and cognitive impairment in animal models of schizophrenia. Eur Neuropsychopharmacol 2014;24:1698–708
  13. Penschuck S, Flagstad P, Didriksen M, Leist M, Michael-Titus AT. Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia. Eur J Neurosci 2006;23:279–84
  14. Lipska BK, Jaskiw GE, Braun AR, Weinberger DR. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Biol Psychiatry 1995;38:255–62
  15. Tseng KY, Chambers RA, Lipska BK. Neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res 2009;204:295–305
  16. Flagstad P, Mork A, Glenthoj BY, van Beek J, Michael-Titus AT, Didreksen M. Disruption of neurogenesis on gesta